DE69633392D1 - Verwendung von betalycan zur verminderung der narbenbildung - Google Patents

Verwendung von betalycan zur verminderung der narbenbildung

Info

Publication number
DE69633392D1
DE69633392D1 DE69633392T DE69633392T DE69633392D1 DE 69633392 D1 DE69633392 D1 DE 69633392D1 DE 69633392 T DE69633392 T DE 69633392T DE 69633392 T DE69633392 T DE 69633392T DE 69633392 D1 DE69633392 D1 DE 69633392D1
Authority
DE
Germany
Prior art keywords
pct
date
betalycan
sec
reduce scars
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69633392T
Other languages
English (en)
Other versions
DE69633392T3 (de
DE69633392T2 (de
Inventor
William Ferguson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Renovo Ltd
Original Assignee
Renovo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10778809&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69633392(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Renovo Ltd filed Critical Renovo Ltd
Publication of DE69633392D1 publication Critical patent/DE69633392D1/de
Application granted granted Critical
Publication of DE69633392T2 publication Critical patent/DE69633392T2/de
Publication of DE69633392T3 publication Critical patent/DE69633392T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Prostheses (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)
  • Preparing Plates And Mask In Photomechanical Process (AREA)
  • Eye Examination Apparatus (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • External Artificial Organs (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Treatment Of Water By Ion Exchange (AREA)
DE69633392T 1995-08-04 1996-07-31 Verwendung von betalycan zur verminderung der narbenbildung Expired - Lifetime DE69633392T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9516073A GB2304045A (en) 1995-08-04 1995-08-04 Betaglycan compositions for promoting the healing of wounds and fibrotic diseases
GB9516073 1995-08-04
PCT/GB1996/001841 WO1997005892A1 (en) 1995-08-04 1996-07-31 Use of betaglycan to reduce scarring

Publications (3)

Publication Number Publication Date
DE69633392D1 true DE69633392D1 (de) 2004-10-21
DE69633392T2 DE69633392T2 (de) 2005-09-22
DE69633392T3 DE69633392T3 (de) 2009-08-13

Family

ID=10778809

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69633392T Expired - Lifetime DE69633392T3 (de) 1995-08-04 1996-07-31 Verwendung von betalycan zur verminderung der narbenbildung

Country Status (13)

Country Link
US (1) US6060460A (de)
EP (1) EP0841937B2 (de)
JP (1) JP4189030B2 (de)
AT (1) ATE275964T1 (de)
AU (1) AU717204B2 (de)
CA (1) CA2228650A1 (de)
DE (1) DE69633392T3 (de)
DK (1) DK0841937T4 (de)
ES (1) ES2227601T5 (de)
GB (1) GB2304045A (de)
PT (1) PT841937E (de)
WO (1) WO1997005892A1 (de)
ZA (1) ZA966577B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2304047A (en) * 1995-08-09 1997-03-12 Univ Manchester Pharmaceutical compositions containing cytokines
EP1237565B1 (de) * 1999-12-15 2006-03-08 Research Development Foundation Betaglycan als ein inhibin rezeptor und dessen verwendung
WO2002030432A1 (en) * 2000-06-23 2002-04-18 Cambridgemed, Inc Agent for reduction of scar formation by using wound alkalinization
GB0309064D0 (en) 2003-04-22 2003-05-28 Univ Manchester Modified peptides and their uses
GB0426960D0 (en) 2004-12-08 2005-01-12 Ares Trading Sa TGR-3 like protein receptor
GB0724231D0 (en) * 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
WO2019236837A1 (en) * 2018-06-06 2019-12-12 Emory University Compositions of Transforming Growth Factor-Beta Type III Receptor and Uses for Ossification

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69030956T2 (de) † 1989-09-29 1998-01-15 La Jolla Cancer Research Foundation, La Jolla, Calif. Inhibierung des Transformierenden Wachstumsfaktors zur Verhinderung der Anhäufung Extrazellulärer Matrix
WO1991010727A1 (en) † 1990-01-22 1991-07-25 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
ES2191007T3 (es) † 1991-10-31 2003-09-01 Whitehead Biomedical Inst Receptor tipo iii de tgf-beta, cdna que lo codifica y sus usos.
AU673506B2 (en) † 1991-11-14 1996-11-14 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors and methods for preventing or reducing scarring
AU3178893A (en) * 1991-11-15 1993-06-15 Memorial Sloan-Kettering Cancer Center Purified proteoglycan betaglycan, compositions, and methods
GB9206861D0 (en) * 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
JPH08504763A (ja) * 1992-10-29 1996-05-21 セルトリックス ファーマシューティカルズ，インコーポレイテッド 治療薬としてのＴＧＦ−βレセプターフラグメントの使用
US5453492A (en) * 1993-07-28 1995-09-26 La Jolla Cancer Research Foundation 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
AU8016894A (en) * 1993-10-15 1995-05-04 La Jolla Cancer Research Foundation Betaglycan polypeptides having tgf-beta binding activity

Also Published As

Publication number Publication date
EP0841937B1 (de) 2004-09-15
DE69633392T3 (de) 2009-08-13
EP0841937A1 (de) 1998-05-20
GB9516073D0 (en) 1995-10-04
US6060460A (en) 2000-05-09
JP2000500162A (ja) 2000-01-11
AU6624996A (en) 1997-03-05
ZA966577B (en) 1998-02-02
JP4189030B2 (ja) 2008-12-03
DK0841937T4 (da) 2009-05-11
WO1997005892A1 (en) 1997-02-20
ES2227601T5 (es) 2009-06-08
ATE275964T1 (de) 2004-10-15
AU717204B2 (en) 2000-03-23
DE69633392T2 (de) 2005-09-22
EP0841937B2 (de) 2009-01-14
DK0841937T3 (da) 2004-10-18
PT841937E (pt) 2004-11-30
ES2227601T3 (es) 2005-04-01
GB2304045A (en) 1997-03-12
CA2228650A1 (en) 1997-02-20

Similar Documents

Publication Publication Date Title
DE69625516D1 (de) Verwendung von il-10 zur wundheilung mit verminderter narbenbildung
DE69317578D1 (de) Verwendung von riluzole zur behandlung von traumatischen neurologischen-schädigungen
DE59611411D1 (de) Verwendung von alpha 1l-agonisten zur behandlung der harninkontinenz
DK0592562T3 (da) BMP-9-præparater
ATE225176T1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
DE69711078D1 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
DE69821793D1 (de) Neuronale verwendungen des bmp-11
DE69633392D1 (de) Verwendung von betalycan zur verminderung der narbenbildung
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
ATE298579T1 (de) Phosphnatanaloge von mannose-6-phosphate und deren verwendung zur förderung der heilung von wunden oder fibrotischen störungen mit verminderter narbenbildung
PT855916E (pt) Composicao farmaceutica contendo um estimulador de activina ou inibina
ATE227995T1 (de) Verwendung von pseudopterosin zur förderung der wundheilung
DE3778158D1 (de) Inhibitoren von esterase produzierenden mikroorganismen zur hauptverwendung in deodorants.
DE59805246D1 (de) Tissue-faktor zur beeinflussung von gefässbildung
ATE184199T1 (de) Verwendung von lokal appliziertem faktor xiii zur verhinderung von blutungen
DK0895478T3 (da) Bestanddel B som ardanner
DE60012718D1 (de) Prognose von ptp lar vermittelten krankheiten
ATE74503T1 (de) Inhibitoren von esterase produzierenden mikroorganismen zur hauptverwendung in deodorants.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings
8328 Change in the person/name/address of the agent

Representative=s name: MARKS & CLERK, LUXEMBOURG, LU